Genomic aberrations relate early and advanced stage ovarian cancer
Zaal, Afra × Peyrot, Wouter J Berns, P M J J van der Burg, Maria E L Veerbeek, Jan H W Trimbos, J Baptist Cadron, Isabelle van Diest, Paul J van Wieringen, Wessel N Krijgsman, Oscar Meijer, Gerrit A Piek, Jurgen M J Timmers, Petra J Vergote, Ignace Verheijen, René H M Ylstra, Bauke Zweemer, Ronald P On behalf of the EORTC GCG Translational Research Group #
Cellular Oncology vol:35 issue:3 pages:181-188
BACKGROUND: Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. METHODS: Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. RESULTS: The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p = 0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p = 0.001), and that did differ significantly in survival (p = 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. CONCLUSION: This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients.